CO-EX COMBINATION PRODUCT SYRUP

Indications

• Cough
• Bronchitis
• Asthma
• Respiratory tract infections
• Inflammatory conditions

Dosage

Children: Refer to established guidelines or consult a healthcare professional for appropriate dosing.

Adults: Refer to established guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

The primary active components of Adhatoda, particularly vasicine and vasicinone, exhibit bronchodilator effects by relaxing the bronchial smooth muscles. They also act as mucolytics, facilitating the clearance of mucus from the respiratory tract. Furthermore, these compounds have been shown to exert anti-inflammatory effects by inhibiting the release of pro-inflammatory cytokines and mediators. This multi-faceted mechanism makes Adhatoda effective in alleviating symptoms associated with respiratory ailments.

Pharmacodynamics

Adhatoda demonstrates a range of pharmacodynamic effects, including bronchodilation, mucus secretion modulation, and anti-inflammatory action. The alkaloids enhance ciliary action in the respiratory tract, improving mucus clearance. The anti-inflammatory properties reduce airway inflammation, which is beneficial in conditions such as asthma and chronic bronchitis. Additionally, the antimicrobial activity of Adhatoda may help in preventing secondary infections in respiratory diseases.

Pharmacokinetics

The pharmacokinetics of Adhatoda have not been extensively studied. However, it is known that the active compounds are absorbed after oral administration, with effects typically observed within hours. The metabolic pathways of vasicine and other alkaloids involve hepatic metabolism, and they are likely excreted in urine. The bioavailability and half-life of these compounds require further investigation to establish precise pharmacokinetic profiles.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Dizziness
• Headache
• Skin rash

Interactions

• May interact with anticoagulants, increasing the risk of bleeding
• Potential interaction with antihypertensive medications

Precautions

• Use with caution in patients with a history of gastrointestinal disorders
• Should be used cautiously in patients with liver disease
• Monitor for potential allergic reactions

Pregnancy

Ahdatoda should be used cautiously during pregnancy. Consultation with a healthcare provider is recommended.

Breast-feeding

Safety during breastfeeding has not been established; consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Dried leaves
• Powdered form
• Extracts

Indications

• Bronchitis
• Cough relief
• Respiratory stimulation
• Bronchial asthma (adjunct treatment)

Dosage

Children: Dosage must be determined based on the child's age, weight, and specific clinical condition. Consult pediatric dosing guidelines or a healthcare professional for appropriate dosing.

Adults: Dosage varies depending on the specific formulation and indication. Refer to relevant medical guidelines or literature for specific dosing recommendations.

Mechanism of action

The active compounds in Aspidosperma, primarily the alkaloids, are thought to act by stimulating the respiratory center in the brain, enhancing respiratory drive. They may also exhibit bronchodilator effects, facilitating improved airflow in the lungs. The specific pathways involve modulation of neurotransmitter release and interactions with adrenergic receptors, promoting increased bronchial smooth muscle relaxation.

Pharmacodynamics

Aspidosperma exhibits a range of pharmacological effects, including respiratory stimulation and potential bronchodilation. The alkaloids may also have mild analgesic and anti-inflammatory properties. Their effects can vary based on the specific species and the concentration of active compounds present in the extracts.

Pharmacokinetics

The pharmacokinetics of Aspidosperma alkaloids are not extensively studied. However, it is known that such compounds are typically absorbed in the gastrointestinal tract, undergo hepatic metabolism, and are excreted primarily via the kidneys. The onset of action and duration can vary based on the formulation and route of administration.

Adverse effects

• Nausea
• Vomiting
• Tachycardia
• Hypertension
• Dizziness
• Headache

Precautions

• Use with caution in patients with cardiovascular disease
• Monitor for potential drug interactions with other cardiovascular medications
• Avoid use in individuals with known hypersensitivity to aspidosperma or its components

Pregnancy

There is insufficient data on the safety of aspidosperma during pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether aspidosperma is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablet
• Liquid extract

Indications

• Anxiety
• Insomnia
• Stress
• Nervous tension
• Hyperactivity

Dosage

Children: Refer to established herbal dosage guidelines, as specific dosing may vary based on the formulation and preparation of incarnata for children. Always consult with a healthcare professional.

Adults: Refer to established herbal dosage guidelines, as specific dosing may vary based on the formulation and preparation of incarnata. Always consult with a healthcare professional.

Mechanism of action

The exact mechanism of action of incarnata is not fully understood, but it is believed to act on the central nervous system. It may enhance the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that promotes relaxation and reduces neuronal excitability. This action is thought to contribute to its calming effects, making it useful in treating anxiety and insomnia.

Pharmacodynamics

Incarnata exhibits sedative, anxiolytic, and muscle relaxant effects. Its active constituents, including flavonoids and alkaloids, may interact with various neurotransmitter systems, primarily modulating GABAergic activity. This leads to a reduction in anxiety levels and an increase in sleep quality. The plant may also possess mild analgesic properties.

Pharmacokinetics

The pharmacokinetics of incarnata are not well-characterized. However, it is generally believed that its active compounds are absorbed in the gastrointestinal tract. The onset of action typically occurs within 30 to 60 minutes when taken orally, and the effects can last several hours. Metabolism occurs primarily in the liver, and excretion is likely through the kidneys, although specific pathways remain to be elucidated.

Adverse effects

• Drowsiness
• Dizziness
• Gastrointestinal upset
• Allergic reactions

Interactions

• Sedatives
• Alcohol
• Antidepressants

Precautions

• Use caution in patients with liver disease
• Use caution in patients with a history of substance abuse
• Not recommended for use in children without medical supervision

Pregnancy

Safety in pregnancy has not been established, use only if clearly needed.

Breast-feeding

Consult a healthcare provider, as safety in breastfeeding is not well established.

Storage

Store in a cool, dry place, away from light and moisture.

Formulations

• Capsules
• Tablets
• Liquid extract

Indications

• Acute poisoning
• Overdose of certain toxins
• As an emetic in specific clinical scenarios

Dosage

Children: For children, the dosage is typically 10 to 15 mL of syrup of ipecac for children aged 1 year and older. Again, it is crucial to seek guidance from a poison control center or healthcare provider.

Adults: For adults, the typical dose for inducing emesis is 15 to 30 mL of syrup of ipecac, taken orally. However, due to the risks associated with its use, consultation with a poison control center or healthcare provider is recommended for specific situations.

Mechanism of action

Ipecacuanha contains alkaloids such as emetine and cephaeline, which stimulate the chemoreceptor trigger zone in the medulla oblongata, leading to the induction of vomiting. These compounds also increase gastric motility and secretions, further contributing to its emetic effect.

Pharmacodynamics

The emetic action of ipecacuanha is dose-dependent, with lower doses potentially causing nausea without vomiting, while higher doses can lead to significant emesis. Its effects are mediated through the central nervous system and gastrointestinal tract.

Pharmacokinetics

Ipecacuanha is absorbed through the gastrointestinal tract, with peak plasma concentrations occurring within 1-3 hours after administration. The elimination half-life and specific metabolic pathways of the active components are not well characterized, but they are believed to be metabolized in the liver and excreted primarily in urine.

Contra-indications

• Hypersensitivity to ipecacuanha
• Use in patients with a known or suspected bowel obstruction
• Concurrent use of emetics or in cases of poisoning with corrosive substances

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Drowsiness
• Cardiac arrhythmias
• Hypotension

Interactions

• May interact with other emetics or central nervous system depressants
• Potential for altered absorption of orally administered medications due to vomiting

Precautions

• Use with caution in patients with a history of cardiac issues
• Monitor for dehydration due to vomiting
• Not recommended for use in children without professional supervision

Pregnancy

Ipecacuanha is not recommended during pregnancy due to potential for adverse effects.

Breast-feeding

Caution is advised when using ipecacuanha while breastfeeding, as it may affect the infant.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Syrup
• Powder
• Capsules

Indications

• Anti-inflammatory treatment
• Antimicrobial therapy
• Pain relief
• Supportive therapy in respiratory conditions
• Traditional medicine for digestive issues

Dosage

Children: Refer to specific herbal product guidelines or consult a qualified herbalist for appropriate dosing.

Adults: Refer to specific herbal product guidelines or consult a qualified herbalist for appropriate dosing.

Mechanism of action

The mechanism of action of Justicia is not well-defined in scientific literature. However, it is believed that the bioactive compounds present in Justicia may exert their effects by modulating inflammatory pathways and inhibiting microbial growth. Some studies suggest that flavonoids and other phytochemicals found in Justicia may possess antioxidant properties, contributing to its therapeutic potential.

Pharmacodynamics

The pharmacodynamics of Justicia largely depend on the specific compounds present in the plant species used. Generally, the anti-inflammatory effects may be mediated through the inhibition of pro-inflammatory cytokines and enzymes, while antimicrobial activity could involve disruption of microbial cell membranes or interference with metabolic processes in pathogens. The exact relationship between dosage, plasma concentration, and therapeutic effect remains to be fully elucidated.

Pharmacokinetics

Limited pharmacokinetic data is available for Justicia, as studies often focus on specific compounds rather than the whole plant. However, it is expected that the absorption, distribution, metabolism, and excretion of Justicia's active constituents would be influenced by factors such as the mode of administration, solubility, and individual patient characteristics. Further investigations are needed to clarify the pharmacokinetics of Justicia extracts and their components.

Pregnancy

Insufficient data available to determine safety in pregnancy.

Breast-feeding

Insufficient data available; caution is advised while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Anxiety disorders
• Insomnia
• Stress-related conditions
• Nervous tension
• Restlessness

Dosage

Children: Refer to established guidelines or consult a healthcare professional for specific dosing recommendations. Caution is advised when using herbal supplements in children.

Adults: Refer to established guidelines or consult a healthcare professional for specific dosing recommendations. Standardized extracts are commonly used in clinical practice.

Mechanism of action

The exact mechanism of action of Passiflora is not fully understood. However, it is believed to exert its effects primarily through modulation of gamma-aminobutyric acid (GABA) receptors. This interaction may enhance GABAergic activity, leading to anxiolytic and sedative effects. Additionally, Passiflora may influence serotonin and dopamine pathways, contributing to its mood-stabilizing properties.

Pharmacodynamics

Passiflora exhibits anxiolytic, sedative, and possibly muscle-relaxant effects. Its active constituents, such as flavonoids and alkaloids, are thought to play a role in its pharmacological effects. Clinical studies suggest that Passiflora may reduce anxiety levels and improve sleep quality without significant sedation, making it a preferred option for patients seeking relief from mild to moderate anxiety without the side effects commonly associated with synthetic anxiolytics.

Pharmacokinetics

The pharmacokinetics of Passiflora are not well-characterized due to the complexity of its composition and the presence of various bioactive compounds. However, it is generally believed that the active constituents are absorbed in the gastrointestinal tract after ingestion, with effects typically noted within an hour. The elimination half-life of Passiflora metabolites is not well-defined, and further research is needed to clarify its metabolism and excretion pathways.

Adverse effects

• Drowsiness
• Dizziness
• Confusion
• Nausea
• Vomiting
• Allergic reactions

Interactions

• May enhance the effects of sedatives and CNS depressants
• Potential interaction with anticoagulants
• May interfere with the metabolism of certain medications processed by the liver

Precautions

• Use with caution in patients with liver disease
• Monitor for increased sedation when used with other CNS depressants
• Not recommended for use in children without medical supervision

Pregnancy

There is insufficient data on the safety of passiflora during pregnancy. It is advised to avoid use unless directed by a healthcare provider.

Breast-feeding

There is limited information on the safety of passiflora while breastfeeding. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Dried herb
• Tincture
• Extracts
• Capsules
• Tablets

Indications

• Cough
• Bronchitis
• Respiratory tract irritation
• Inflammation

Dosage

Children: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Adults: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

The primary bioactive components in quebracho are condensed tannins, which exert astringent effects. These tannins can bind to proteins and other macromolecules, potentially leading to a reduction in inflammation and irritation in the respiratory tract. Additionally, some studies suggest that quebracho may modulate mucus production and enhance respiratory function, although the exact pathways remain to be fully elucidated.

Pharmacodynamics

Quebracho exhibits anti-inflammatory and astringent properties. The tannins interact with epithelial tissues of the respiratory tract, which may help to decrease inflammation and promote a soothing effect. Its cough-suppressant action may be attributed to the reduction of irritation in the throat and airways, leading to decreased cough reflex activity.

Pharmacokinetics

The pharmacokinetics of quebracho have not been extensively studied in humans. However, it is known that tannins can be poorly absorbed in the gastrointestinal tract, leading to limited systemic availability. The effects are primarily local, acting in the gut and respiratory system. The metabolism of tannins involves complex pathways including hydrolysis and microbial degradation, with possible interactions with gut microbiota influencing their bioactivity.

Pregnancy

There is insufficient evidence regarding the safety of quebracho during pregnancy. Consult a healthcare provider for individual assessment.

Breast-feeding

Due to limited data on the excretion of quebracho in breast milk and its effects on the infant, caution is advised. Consult a healthcare provider.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Dosage

Children: Dosage information is not available due to the lack of a recognized drug profile.

Adults: Dosage information is not available due to the lack of a recognized drug profile.

Pregnancy

Safety in pregnancy has not been established. Consult with a healthcare professional before use.

Breast-feeding

Safety during breastfeeding is not well established. Consult with a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight and moisture.

Indications

• Cognitive enhancement
• Increased physical endurance
• Antioxidant support
• Mood elevation

Dosage

Children: Refer to established guidelines for caffeine intake in children. Generally, caffeine consumption is not recommended for young children.

Adults: Refer to established guidelines for caffeine intake. Generally, moderation is advised.

Mechanism of action

Yerba mate contains several bioactive compounds, including caffeine, theobromine, and polyphenols. Caffeine acts as a central nervous system stimulant by antagonizing adenosine receptors, which enhances alertness and reduces fatigue. Theobromine may contribute to mood enhancement and relaxation effects, while polyphenols offer antioxidant protection.

Pharmacodynamics

The pharmacodynamic effects of yerba mate are largely attributed to its caffeine content, which can increase heart rate and blood pressure temporarily. It may also enhance physical performance and improve cognitive function. The antioxidants in yerba mate may help reduce inflammation and oxidative stress.

Pharmacokinetics

Caffeine is rapidly absorbed after ingestion, with peak plasma concentrations typically occurring within 1-2 hours. It is metabolized primarily in the liver by cytochrome P450 enzymes, particularly CYP1A2. The half-life of caffeine varies widely among individuals, ranging from 3 to 7 hours, influenced by factors such as age, liver function, and genetic polymorphisms. Yerba mate's other components, such as theobromine, also exhibit variable absorption and metabolism.

Adverse effects

• Insomnia
• Nervousness
• Stomach upset
• Headaches
• Increased heart rate
• High blood pressure
• Gastrointestinal disturbances

Interactions

• Caffeine-containing products may enhance stimulant effects
• Anticoagulants may have increased bleeding risk
• Monoamine oxidase inhibitors (MAOIs) may cause hypertensive reactions
• Stimulants may increase the risk of cardiovascular side effects

Precautions

• Use with caution in individuals with cardiovascular disorders
• May cause gastrointestinal irritation
• Monitor for side effects in patients with anxiety or sleep disorders

Pregnancy

Yerba mate should be avoided during pregnancy due to potential stimulant effects and insufficient safety data.

Breast-feeding

Caution is advised as caffeine can pass into breast milk; consult a healthcare professional.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Loose leaf tea
• Tea bags
• Powdered extract
• Ready-to-drink beverages